SEC Comment Letter 0000000000-24-004255 to Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI)
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: April 18, 2024 · CIK: 0001503802 · Accession: 0000000000-24-004255
AI Filing Summary & Sentiment
File numbers found in text: 001-36167
Letter
United States securities and exchange commission logo April 18, 2024 Michael Mason EVP, Chief Financial Officer and Treasurer Karyopharm Therapeutics Inc. 85 Wells Ave., 2nd Floor Newton, MA 02459 Re:Karyopharm Therapeutics Inc. Form 10-K for the year ended December 31, 2023 Filed February 29, 2024 File No. 001-36167 Dear Michael Mason: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 18, 2024
Michael Mason
EVP, Chief Financial Officer and Treasurer
Karyopharm Therapeutics Inc.
85 Wells Ave., 2nd Floor
Newton, MA 02459
Re:Karyopharm Therapeutics Inc.
Form 10-K for the year ended December 31, 2023
Filed February 29, 2024
File No. 001-36167
Dear Michael Mason:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences